BioSpace News Archive

After an extensive search for the top changemakers in six key U.S. cities, Johnson & Johnson announced the 14 awardees of its Health Equity Innovation Challenge.

Pivotal trial to study the safety and efficacy of sacral nerve stimulation in patients with urinary urgency incontinence symptoms.

Award Recognizes the Company’s Verita ™ Isolation Platform, which Enables Early-Stage Cancer Detection.

Pear Therapeutics Announces New 12-Month Analysis Showing Reduction in Healthcare Resource Utilization and Associated Costs in Patients Treated with reSET-O ® .

MAIA Biotechnology, Inc. , a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs (“MAIA”), announced today that MAIA has entered into a research and collaboration agreement with the Nationwide Children’s Hospital to evaluate the potential of THIO in combination with current standard-of-care therapies for cancer.

Momentum continues to build for Dren Bio after successfully forming highly experienced senior leadership team and earlier this year announcing research collaboration and license deal with Pfizer.

Pre-clinical proof-of-concept demonstrated in a disease model.

Blue Earth Therapeutics Announces Promising Results of Preclinical Biodistribution and Efficacy Evaluation of 177 Lu-rhPSMA-10.1 in Treatment of Prostate Cancer.

seqWell, a global provider of genomic library workflow solutions including the plexWell™ next-generation sequencing (NGS) multiplexing technology, today announced the appointment of Dr Amy Liao to its Board.

Prolacta Bioscience® announced the introduction of the first evidence-based feeding protocol for the use of an Exclusive Human Milk Diet including Prolacta’s products in the neonatal intensive care unit.